Shanghai, China, October 23, 2025 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, today announced the appointment of Mr. Baohua Chen as Executive Vice President of Finance. In this role, Mr. Chen will lead the company’s strategic financial planning, capital markets and investor relations, financial operations and controls, strategic partnerships and M&A, as well as commercial finance and operational support. He will report directly to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris.
Mr. Baohua Chen, Executive Vice President of Finance, Asieris Pharmaceuticals
Mr. Baohua Chen brings over 20 years of diversified financial management experience across the pharmaceutical, medical device, and IT industries.. Prior to joining Asieris, he served as Vice President of Finance at Edding Group, where he led the Group’s financial operations and supported its end-to-end R&D, manufacturing, and commercialization activities across global markets, covering both in-house developed and licensed-in innovative drugs. He also played a key role in several major capital initiatives, including domestic and international bond financing, a reverse takeover, and an HKEX IPO project. Before that, Mr. Chen held Senior Finance Director for Medtronic Greater China and concurrently as Chief Financial Officer of the group’s acquired company, Changzhou Kangdi Stapler Co., Ltd., where he was responsible for financial operations, strategic planning, and post-merger integration.
Dr. Kevin Pan commented, “We are delighted to welcome Mr. Baohua Chen to Asieris. With extensive experience in financial management across both domestic biopharmaceutical companies and multinational pharmaceutical corporations, Mr. Chen has demonstrated outstanding achievements in financial strategy, operations, and capital markets. We are confident that his exceptional strategic leadership and profound professional expertise will strengthen our financial leadership, create sustained long-term value for the company, and support Asieris in achieving its long-term strategic goals.”
Mr. Baohua Chen said, “I am honored to join Asieris at such a pivotal stage of its growth. I deeply admire the company’s mission and its expertise in genitourinary oncology and women’s health. Moving forward, I will draw on my experience in financial management and capital markets to work closely with the team in strengthening our financial foundation, expanding capital access, and supporting the company’s long-term, sustainable development.”
Mr. Chen holds a Bachelor’s degree in Economics from Shanghai University of Finance and Economics, an MBA from the China Europe International Business School(CEIBS), and is a member of the Chartered Institute of Management Accountants (CIMA).
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and women’s health. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus.
Through proprietary R&D and strategic collaborations, the company is committed to developing first-in-class drugs and other innovative technologies and products that address significant unmet medical needs, building a robust portfolio spanning from disease diagnosis to treatment within its focused therapeutic areas. Driven by patient needs, we are comprehensively advancing Commercialization 2.0 to improve the accessibility and affordability of innovative products, thereby benefiting more patients in China and globally.